Latest Sirtex Stories

SYDNEY, December 11, 2012 /PRNewswire/ -- http://www.sirtex.com informs doctors, patients and investors about the world's most widely used and widely studied form of SIRT for all cancers in the liver Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining...

MAGDEBURG, Germany, October 21, 2012 /PRNewswire/ -- Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note The results of a matched-pair comparison of patients with metastatic colorectal cancer predominately affecting the liver, for whom all chemotherapy options had been exhausted, showed that the addition of radioembolization using SIR-Spheres...

PARIS, February 3, 2012 /PRNewswire/ -- 'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment The start of SARAH, a new randomized controlled trial to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (SIR-Spheres(R) microspheres; Sirtex Medical...

PAMPLONA, Spain, July 7, 2011 /PRNewswire/ -- Results of the multi-centre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) analysis of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres in patients with inoperable primary liver tumours were published on-line today in Hepatology, the peer-reviewed journal of the American Association of the Study of Liver Diseases.[1] Evaluation of 325 patients with...

More than 170 physicians and health care professionals specializing in the treatment of liver metastases gathered May 2-3 in Chicago for the fourth annual clinical symposium on liver-directed microsphere therapy. The symposium, sponsored by the Goshen Center for Cancer Care, was supported by an educational grant provided by Sirtex Medical. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for colorectal liver metastases.(1) "Sirtex has supported the...

A review article, published in the July issue of Archives of Surgery, an international peer-reviewed journal, examines the use of Sirtex's SIR-Spheres® microspheres in patients with hepatic colorectal cancer metastases. According to the review, the use of SIR-Spheres microspheres is effective in improving response rates and extending survival times in patients with colorectal cancer liver metastases. Sirtex's SIR-Spheres microspheres are currently FDA approved to treat colorectal...